Preclinical characterization of MTX-101: a novel bispecific CD8 Treg modulator that restores CD8 Treg functions to suppress pathogenic T cells in autoimmune diseases.
Gardell JL, Maurer ME, Childs MM, Pham MN, Meengs B, Julien SH, Tan C, Boster DR, Quach P, Therriault JH, Hermansky G, Patton DT, Bowser J, Chen A, Morgan NN, Gilbertson EA, Bogatzki L, Encarnacion K, McMahan CJ, Crane CA, Swiderek KM.
Gardell JL, et al. Among authors: morgan nn.
Front Immunol. 2024 Nov 4;15:1452537. doi: 10.3389/fimmu.2024.1452537. eCollection 2024.
Front Immunol. 2024.
PMID: 39559361
Free PMC article.